Semaglutide
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist composed of a modified peptide sequence designed to enhance stability and receptor binding. It is commonly utilized in research settings to study metabolic regulation and glucose signaling pathways. Supplied by Peptico for research-use only.
All Orders Ship within
24 Business Hours
Free Shipment Protection
Priority Shipment Options Available at Checkout
Format
Lyophilized powder
Approved Exclusively For
Laboratory and Analytical Research
Handling
Utilize appropriate sterile technique and controlled environments during preparation.
Short-Term Storage - Lyophilized Powder Form Only
- For maximum potency, lyophilized materials may generally be stored between 2°C and 8°C (36°F to 46°F) for up to 4 weeks when maintained in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
Long-Term Storage - Lyophilized Powder Form Only
- For maximum potency and long-term preservation, lyophilized materials may generally be stored between -20°C and -80°C (-4°F to -112°F) for up to 1 year when preserved in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
Important Note:
Storage guidelines apply only to lyophilized material in its original, sealed, and untampered vial.
COA History
All shipped products include a unique batch number printed on the vial label. This batch number corresponds to a third-party Certificate of Analysis tested by an ISO/IEC 17025 accredited laboratory.
The COA attached at the top of this page, along with the COA marked “Current” below, represents the active production batch currently being shipped. This same batch number will appear on the label of your vial.
For previous purchases, please refer to COAs marked “Historical” and match the batch number on your vial to the batch number listed on the corresponding COA.
For a complete record of testing documentation across all products and batches, please visit our COA Vault, which includes both current and historical COAs.
Loading COA history...
Molecular Profile
What is Semaglutide?
Scientific compound data sourced from PubChem.
Chemical Structure
PubChem CID 56843331
Type
Chemical compound
PubChem CID
56843331
CAS Number
910463-68-2
Molecular Formula
C187H291N45O59
Molecular Weight
4114.00 g/mol
IUPAC Name
18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
InChIKey
DLSWIYLPEUIQAV-CCUURXOWSA-N
Research
Sources & References
API results related to Semaglutide.
PubChem
Compound data
Semaglutide compound record
CID: 56843331
Formula: C187H291N45O59 • Molecular weight: 4114
View source
PubMed
Scientific paper
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economics
Publication date: 2026 Dec
View source
PubMed
Scientific paper
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicine
Publication date: 2026 Dec
View source
PubMed
Scientific paper
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health care
Publication date: 2026 Dec
View source
PubMed
Scientific paper
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
Journal of medical economics
Publication date: 2026 Dec
View source
PubMed
Scientific paper
Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.
Renal failure
Publication date: 2026 Dec
View source⚠️ IMPORTANT RESEARCH NOTICE
This product is NOT for human consumption.
Supplied strictly for laboratory and analytical research use only, it is not intended to diagnose, treat, cure, or prevent any disease, and must not be used for clinical, veterinary, or therapeutic applications.
All information provided, including referenced research and data, is for educational and scientific context only and should NOT be interpreted as medical guidance.
By purchasing, you confirm that you are a qualified individual or entity operating in accordance with applicable local, state, and federal regulations. All responsibility for handling, use, and compliance rests solely with the purchaser.
